CCGCRN COHORT

RESEARCH PUBLICATIONS & ABSTRACTS

1. Slavin TP, Niell-Swiller M, Solomon…Weitzel JN. (2015) Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management. *Frontiers in Oncology*. 5:208. PMCID: PMC4586434

2. Kwong A, Shin V, Ho J…Weitzel JN, et al. (2015 [Epub ahead of print]) Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. *Journal of Medical Genetics.* NIHMS ID: NIHMS721868

3. Goodenberger ML, Thomas BC, Riegert-Johnson D … Weitzel JN, et al. (2015 [Epub ahead of print]) PMS2 monoallelic mutation carriers: the known unknown. *Genet Med*. doi: 10.1038/gim.2015.27.

4. Rebbeck TR, Antoniou AC, Nathasonson KL,…Weitzel JN, et al. (2015) Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA.* 313(13):1347-61. PMCID: PMC4537700

5. Santa Cruz Guindalini R, Win AK, Gulden C…Weitzel JN, et al. (2015 [Epub ahead of print]) Mutation Spectrum and Risk of Colorectal Cancer in African American Families with Lynch Syndrome. *Gastroenterology*. NIHMS ID: NIHMS712911

6. Hart SN, Maxwell KN, Thomas T…Weitzel JN, et al. (2015[Epub ahead of print]) Collaborative science in the next-generation sequencing era: a viewpoint on how to combine exome sequencing data across sites to identify novel disease susceptibility genes. *Brief Bioinform*. doi: 10.1093/bib/bbv075

7. Villarreal-Garza C, Weitzel JN, et al. (2015)The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer*. Breast Cancer Res Treat*. 150(2):389-94. PMCID: PMC4532439.

8. Kuchenbaecker KB, Ramus SJ, Tyrer J … Weitzel JN, et al. (2015) Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature genetics*. 47(2):164-71. PMCID: PMC4445140

9. Blein S, Bardel C, Danjean V…Weitzel JN,et al (2015). An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*. 17(1):61. PMCID: PMC4478717

10. Blanco I, Kuchenbaecker K, Cuadras D…Weitzel JN, et al. (2015) Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. *PLoS One*. 10(4):e0120020. PMCID: PMC4382299

11. Hollestelle A, van der Baan FH, Berchuck A … Weitzel JN, et al (2015 [Epub ahead of print]) No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecol Oncol*. doi: 10.1016/j.ygyno.2015.04.034.

12. Peterlongo P, Chang-Claude J, Moysich KB …Weitzel JN, et al. (2015) Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiol Biomar*. 24(1):308-16. PMCID: PMC4294951.

13. Semple J, Metcalfe K, Lubinski J …Hereditary Breast Cancer Clinical Study Group. (2015) Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers? *Breast Cancer Research and Treatment*, 154(1):163-169.

14. Antoniou AC, Casadei S, Heikkinen T …Weitzel JN, et al. (2014) Breast-Cancer Risk in Families with Mutations in PALB2. *New Engl J Med*. 371(6):497-506. PMCID: PMC4157599.

15. Abugattas J, Llacuachaqui M, Allende YS …Weitzel JN, Narod SA (2014) Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru. *Clin Genet*. 88(4):37-15. PMCID: PMC4374018

16. Narod SA, Tung N, Lubinski J …Hereditary Breast Cancer Clinical Study Group (2014) A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers. *Curr Oncol*, 21(2): 64-8. PMCID:PMC3997444

17. Kotsopoulos J, Lubinski J, Gronwald J … Weitzel JN, et al. (2014 [epub ahead of print]) Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. *Int J Cancer*, PMCID: PMC4458227

18. Chai X, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C,…Weitzel JN, et al. (2014 [ePub ahead of print]) Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. *Breast Cancer Res Treat*. PMCID: PMC4224991.

19. Hernandez JE, Llacuachaqui M, Palacio G,…Weitzel, JN Narod SA. (2014 [ePub ahead of print]) Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Medellin, Colombia. *Hered Cancer Clin Pract*. 12(1):11. PMCID: PMC3998735

20. Osorio A, Milne RL, Vaclová T, Pita G, …Weitzel, JN et al. (2014) DNA glycosylases involved in Base Excision Repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. *PLOS Genetics*, 10(4):e1004256. PMCID: PMC3974638.

21. Villarreal-Garza C, Alvarez-Gómez RM, Pérez-Plasencia C …Weitzel JN (2015) Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico. *Cancer*, 121(3):372-8.PMCID: PMC4304938.

22. Wain KE, Ellingson MS, McDonald JA, …Weitzel JN, Lindor N. (2014) Appreciating the broad clinical features of SMAD4 mutation carriers: a multicenter chart review. *Genet. Med*. 16(8): p. 588-93. PMCID: PMC4125531.

23. Bojesen SE, Pooley KA, Michailidou K, …Weitzel JN, …Dunning, A. (2013) Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 45(4):371-384. PMCID: PMC3670748.

24. Couch FJ, Wang X, McGuffog L, …Weitzel, JN, …Antoniou, A. (2013) Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. *PLOS Genetics*, 9(3):e1003212. PMCID: PMC3609646.

25. Culver JO, Brinkerhoff CD, Clague J, K. Y, Singh K, Sand SR, Weitzel JN (2013) Variants of Uncertain Significance in BRCA Testing: Evaluation of Surgical Decisions, Risk Perception, and Cancer Distress. *Clin Genet*, 84(5):464-472. PMCID: PMC3751990.

26. Gaudet M, Kuchenbaecker K, Vijai J,…Weitzel JN,…Offit K. (2013) Identification of a BRCA2-specific Modifier Locus at 6p24 Related to Breast Cancer Risk. *PLoS Genet*. PMCID: PMC3609647

27. Laitman, Y., Feng, B.-J., Zamir, I. M., Weitzel, JN., Duncan, P., Port, D., . . . Friedman, E. (2013). Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. European *Journal of Human Genetics*, 21(2):212-216. PMCID: PMC3548269.

28. Southey MC, Park DJ, Nguyen-Dumont T, …Weitzel, JN, et al. COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. *Breast Cancer Research*. 2013;15(3):402. Doi: 10.1186/bcr3434. PMCID: PMC3706918.

29. Valentini A, Lubinski J, Byrski T, …Weitzel, JN, et al. (2013) The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation. *Breast Cancer Res Treat*, 142(1):177-185. PMCID: PMC3940343.

30. Weitzel JN, Clague J, Martir-Negron A, Ogaz R, Herzog J, Ricker C, Jungbluth C, Cina C, Duncan P, Unzeitig G, Saldivar JS, Beattie M, Feldman N, Sand S, Port D, Barragan DI, John EM, Neuhausen SL, Larson GP (2013) Prevalence and Type of BRCA Mutations in Hispanics Undergoing Genetic Cancer Risk Assessment in the Southwestern United States: A Report From the Clinical Cancer Genetics Community Research Network. *J Clin Oncol* 31 (2):210-216. PMCID: PMC3532393.

31. Blazer, K. R., Christie, C., Uman, G., & Weitzel, J. N. (2012). Impact of Web-based Case Conferencing on Cancer Genetics Training Outcomes for Community-based Clinicians. *Journal of Cancer Education*, 27(2), 217-225. PMCID: PMC3857095.

32. Ding YC, McGuffog L, Healey S, Friedman E, Laitman Y,…Weitzel, JN,…Neuhausen, S.L. (2012). A non-synonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers & Prevention*. 21(12):2278. PMCID: PMC3415567.

33. Espenschied CR, MacDonald DJ, Culver JO, Sand S, Hurley K, Banks KC, Weitzel JN, Blazer KR. (2012) Closing the Loop: Action research in a multimodal hereditary cancer patient conference is an effective tool to assess and address patient needs. Journal of Cancer Education, 27(3):467-477. PMCID: PMC3540105.

34. Finkelman BS, Rubinstein WS, Friedman S, …Weitzel JN, …Rebbeck TR. (2012) Breast and Ovarian Cancer Risk and Risk Reduction in Jewish BRCA1/2 Mutation Carriers. J Clin Oncol 30 (12):1321-1328. PMCID: PMC3341145.

35. Kotsopoulos, J., Lubinski, J., Lynch, H. T., Kim-Sing, C., Neuhausen, S, …Weitzel, JN, … Narod, S. A. (2012). Oophorectomy after Menopause and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers & Prevention, 21(7), 1089-1096. PMCID: PMC3593267

36. Liu, J., Cristea, M. C., Frankel, P., Neuhausen, S. L., Steele, L., Engelstaedter, V., ...Weitzel, J. N. (2012). Clinical characteristics and outcomes of BRCA-associated ovarian cancer (OC): genotype and survival. Cancer Genetics, 205(1-2), 34-41. PMCID: PMC3337330.

37. MacDonald DJ, Deri J, Ricker C, Perez MA, Ogaz R, Feldman N, Viveros LA, Paz B, Weitzel JN, Blazer, KR. (2012) Closing the Loop: An interactive action-research conference format for delivering updated medical information while eliciting Latina patient/family experiences and psychosocial needs post-genetic cancer risk assessment. Fam Cancer, 11 (3):449-458. PMCID: PMC3620038.

38. Mai PL, Malkin D, Garber JE, Schiffman JD, Weitzel JN, …Savage SA (2012) Li-Fraumeni syndrome: Report of a clinical research workshop and creation of a research consortium. Cancer Genet 205 (10):479-487. PMCID: PMC3593717

39. Masciari S, Dillon DA, Rath M, Robson M, Weitzel JN, …Garber JE (2012) Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat 133 (3):1125-1130. PMCID: PMC3709568.

40. Newhauser, W. D., Scheurer, M. E., Faupel-Badger, J. M., Clague, J., Weitzel, J., & Woods, K. V. (2012). The Future Workforce in Cancer Prevention: Advancing Discovery, Research, and Technology. Journal of Cancer Education, 27(2), S128-135. PMCID: PMC3349779.

41. Pilarski, R., Patel, D. A., Weitzel, J., McVeigh, T., Dorairaj, J. J., Heneghan, H. M., . . . Shulman, L. P. (2012). The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer. PLoS One, 7(5), e37891. PMCID: PMC3360659.

42. Ratner ES, Keane FK, Lindner R, …Weitzel JN, …Weidhaas JB (2012) A KRAS-variant is a Biomarker of Poor Outcome, Platinum Chemotherapy Resistance and a Potential Target for Therapy in Ovarian Cancer Oncogene 31 (42):4559-4566. PMCID: PMC3342446.

43. Rodríguez, A. O., Llacuachaqui, M., Pardo, G. G., Royer, R., Larson, G., Weitzel, J. N., & Narod, S. A. (2012). BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia. Gynecologic Oncology, 124, 236-243.

44. Stevens K, Wang X, Fredericksen Z, …Hereditary Breast Ovarian Cancer Group, …Couch F. (2012) Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. Breast Cancer Res Treat 136 (1):295-302. PMCID: PMC3342446.

45. Blazer, K. R., MacDonald, D. J., Culver, J. O., Huizenga, C. R., Morgan, R. J., Uman, G. C., & Weitzel, J. N. (2011). Personalized cancer genetics training for personalized medicine: Improving community-based healthcare through a genetically literate workforce Genet Med, 13(9), 832-840. PMCID: PMC3337331.

46. Brown, S. M., Culver, J. O., Osann, K. E., MacDonald, D. J., …Weitzel, JN. (2011). Health literacy, numeracy, and interpretation of graphical breast cancer risk estimates. Patient Educ Couns, 83(1), 92-98.

47. Clague, J., Wilhoite, G., Adamson, A., Bailis, A., Weitzel, J. N., & Neuhausen, S. L. (2011). RAD51C Germline Mutations in Breast and Ovarian Cancer Cases from High-Risk Families. PLoS One, 6(9), e25632. PMCID: PMC3182241.

48. Culver, J. O., MacDonald, D. J., Thornton, A. A., Sand, S. S., Grant, M., Bowen, D. J., . . . Weitzel, J. N. (2011). Development and evaluation of a decision aid for BRCA carriers with breast cancer. Journal of Genetic Counseling, 20(3), 294-307. PMCID: PMC3531556.

49. Duncan, P. R., & Lin, J. T. (2011). Ingredients for success: A familial cancer clinic in an oncology practice setting. Journal of Oncology Practice, 7(1), 39-42. PMCID: PMC3014509

50. Im, KM, ...Weitzel, JN, ...Gold, B. (2011). Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Hum Genet ,130 (5):685-699. PMCID: PMC3196382.

51. Kempers, M. J., Kuiper, R. P., Ockeloen, C. W, …Culver, JO, … Ligtenberg, MJ. (2011). Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol, 12(1), 49-55. PMCID: PMC3670774.

52. Lagos-Jaramillo, V. I., Press, M. F., Ricker, C. N., Dubeau, L., Mai, P. L., Weitzel, J. N. (2011). Pathological characteristics of BRCA-associated breast cancers in Hispanics. Breast Cancer Research and Treatment, 130(1), 281-289. PMCID: PMC3526343.

53. Neuhausen, SL, Brummel, S, Ding, YC, …Weitzel, JN, …Gillen, DL. (2011). Genetic Variation in IGF2 and HTRA1 and Breast Cancer Risk Among BRCA1 and BRCA2 Carriers. Cancer Epidemiology, Biomarkers & Prevention, 8(20), 1690-1702. PMCID: PMC3352680.

54. Rebbeck, T, Mitra, N, Domchek, SM, …Weitzel, JN, ...Nathanson, K. L. (2011). Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Research, 71(17), 5792-5805. PMCID: PMC3170727.

55. Sorrell, A. D., Lee, S., Stolle, C., Ellenhorn, J., Grix, A., Kaelin, W. G., Jr., & Weitzel, J. N. (2011). Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma. Clin Genet, 79(6), 539-545. PMCID: PMC2958253.

56. Spurdle M, Marquart L, McGuffog L,…Weitzel JN,…Rebbeck, T. R. (2011). Common genetic variation at BARD1 is not associated with Breast cancer risk in BRCA1 or BRCA2 mutation carriers. Cancer Epidemiology Biomarkers & Prevention, 20(5), 1032-1038. PMCID: PMC3089675.

57. Weitzel JN, Blazer KR, MacDonald DJ, Culver JO, Offit K (2011) Genetics, Genomics and Cancer Risk Assessment: State of the art and future directions in the era of personalized medicine. CA Cancer J Clin 61 (5):327-359. PMCID: PMC3346864.

58. Antoniou, A. C., Wang, X., Fredericksen, Z. S., McGuffog, L., Tarrell, R., Sinilnikova, OM, ...Weitzel, JN, …Couch, FJ. (2010). A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet, 42(10), 885-892. PMCID: PMC3130795.

59. Antoniou, A. C., Beesley, J., McGuffog, L., Sinilnikova, O. M., Healey, S., Neuhausen, S. L., …Weitzel, J. N, … Easton, DF. (2010). Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res, 70(23), 9742-9754. PMCID: PMC2999830.

60. Audeh MW, …Weitzel JN, …Tutt A. (2010). Oral poly (adp-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet, 376(9737), 245-251.

61. Domchek, S. M., Friebel, T. M., Garber, J. E., Isaacs, C., …Weitzel JN, …Rebbeck, TR (2010). Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat, 124(1), 195-203. PMCID: PMC2949487.

62. Domchek, S. M., Friebel, T. M., Singer, C. F., …Weitzel JN, …Rebbeck, TR. (2010). Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA, 304(9), 967-975. PMCID: PMC2948529.

63. Jasperson, K., Vu, T. M., Schwab, A. L., …Weitzel, JN. (2010). Evaluating Lynch syndrome in very early onset colorectal cancer probands without apparent polyposis. Fam Cancer, 9(2), 99-107. PMCID: PMC3620042

64. MacDonald, D. J., Blazer, K. R., & Weitzel, J. N. (2010). Extending comprehensive cancer center expertise in clinical cancer genetics and genomics to diverse communities: The power of partnership. J Natl Compr Canc Netw, 8(5), 615-624. PMCID: PMC3299537.

65. MacDonald, D. J., Sarna, L., Weitzel, J. N., & Ferrell, B. (2010). Women's perceptions of the personal and family impact of genetic cancer risk assessment: Focus group findings. Journal of Genetic Counseling, 19(2), 148-160.

66. Tutt, A., Robson, M., Garber, J. E., Domchek, S., …Weitzel, JN, …Carmichael, J. (2010). Oral poly (adp-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet, 376(9737), 235-244.

67. McKinnon, W., K. C. Banks, ...Weitzel, JN. (2009). Survey of unaffected BRCA and mismatch repair (MMR) mutation positive individuals. Fam Cancer, 8(4), 363-369. PMCID: PMC3528358

68. Neuhausen S.L., Brummel S., Ding Y.C.,…Weitzel JN, ...Gillen, D. L. (2009). Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Res 11(5): R76. PMCID: PMC2790858.

69. Pal SK, Blazer KR, Weitzel JN, Somlo G. (2009) An association between invasive breast cancer and familial idiopathic hyperparathyroidism: A case series and review of the literature. Breast Cancer Res Treat. 115(1):1-5.

70. Torres, D., Rashid, M. U., Seidel-Renkert, A., Weitzel, JN, (2009). Absence of the BRCA1 del (exons 9-12) mutation in breast/ovarian cancer families outside of Mexican Hispanics. Breast Cancer Res Treat 117(3): 679-81.

71. Antoniou, A. C., A. B. Spurdle, …Weitzel JN, ...Easton, DF. (2008). Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. American journal of human genetics 82(4): 937-948. PMCID: PMC2427217.

72. Jasperson, K., K. Blazer, Lowstuter, K, Weitzel, JN. (2008). Working through a diagnostic challenge: colonic polyposis, Amsterdam criteria, and a mismatch repair mutation. Fam Cancer, 7(4), 281-285.

73. Lagos, V. I., Perez, MA, …Weitzel, JN. (2008). Social cognitive aspects of underserved Latinas preparing to undergo genetic risk assessment for hereditary breast and ovarian cancer. Psycho-Oncology 17(8): 774-782.

74. MacDonald, D. J., L. Sarna, …Weitzel, JN. (2008). Comparison of Latina and non-Latina White women's beliefs about communicating genetic cancer risk to relatives Journal of Health Communication 13(5): 465-79.

75. Mai, P. L., Lagos, VI, Palomares, MR, Weitzel, JN. (2008). Contralateral risk-reducing mastectomy in young breast cancer patients with and without genetic cancer risk assessment. Ann Surg Oncol 15(12): 3415-21. PMCID: PMC2993252

76. Metcalfe, K. A., J. Lubinski, …Weitzel, JN, …Narod, SA. (2008). Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol 26(7): 1093-7.

77. Narod, S. A., S. Neuhausen, ...Weitzel, JN...Sun, P. (2008). Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 99(2): 371-4. PMCID: PMC2993252

78. West, J. G., Weitzel, JN, ...Fanning, C. (2008). BRCA mutations and the risk of angiosarcoma following breast cancer treatment. Clinical Breast Cancer 8(6): 533-7.

79. Antoniou AC, Sinilnikova OM, Simard J, ...Weitzel, JN, ... Chenevix-Trench, G. (2007) RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet. 81(6):1186-1200. PMCID: PMC2276351

80. Couch, F. J., Sinilnikova, O., Vierkant, R. A., ...Weitzel, JN, ...Antoniou, A. (2007). AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a CIMBA study. Cancer Epidemiol Biomarkers Prev, 16(7), 1416-1421.

81. Kotsopoulos J, Lubinski J, Lynch HT,, …Weitzel, JN, Sun, P., Narod, SA. (2007) Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat.105(2):221-228.

82. MacDonald DJ, Sarna L, ...Weitzel, JN. (2007). Selection of family members for communication of cancer risk and barriers to this communication before and after genetic cancer risk assessment. Genet Med. 9(5):275-282.

83. Parmigiani G, Chen S, Iversen ES, …Weitzel, JN, …Euhus, DM. (2007). Validity of models for prediction of BRCA1 and BRCA2 mutations. Annals of Internal Medicine 147, No. 7:441-450.

84. Ricker, C. N., S. Hiyama, …Weitzel, JN. (2007). Beliefs and Interest in Cancer Risk in an Underserved Latino Cohort. Prev Med 44(3): 241-245.

85. Weitzel JN, Lagos VI, Cullinane CA, …MacDonald, DJ. (2007) Limited Family Structure and BRCA Gene Mutation Status in Single Cases of Breast Cancer. JAMA 297(23):2587-2595.

86. Weitzel JN, Lagos VI, Herzog JS, ...Scholl, T. (2007). Evidence for Common Ancestral Origin of a Recurring BRCA1 Genomic Rearrangement Identified in High-risk Hispanic Families. Cancer Epidemiol Biomarkers Prev. 16(8):1615-1620.

87. Jasperson, K. W., Lowstuter, K, Weitzel, JN. (2006). Assessing the Predictive Accuracy of hMLH1 and hMSH2 Mutation Probability Models. J Genet Couns 15(5): 339-47.

88. MacDonald, D. J., Sarna, L. ...Weitzel, JN. (2006). Cancer screening and risk reducing behaviors of women seeking genetic cancer risk assessment for breast and ovarian cancers. Oncol Nurs Forum 33(2): E27-35.

89. MacDonald, D. J., S. Sand, ...Weitzel, JN. (2006). The power of partnership: Extending comprehensive cancer center expertise in clinical cancer genetics to breast care in community centers. Seminars in Breast Disease 9: 39-47.

90. Ricker, C., V. Lagos, ...Weitzel, JN. (2006). If we build it ... will they come? - Establishing a cancer genetics services clinic for an underserved predominantly Latina cohort. J Genet Couns 15(6): 505-14.

91. Cullinane, CA, ...Weitzel, JN, Narod, SA. (2005). The effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. International Journal of Cancer 117(6): 988-91.

92. MacDonald, DJ, Sarna, L., Uman, GC, Grant, M, Weizel, JN. (2005). Health beliefs of women with and without breast cancer seeking genetic cancer risk assessment. Cancer Nurs 28(5): 372-379.

93. Palomares, MR, Paz IB, Weitzel JN. (2005). Genetic cancer risk assessment in the newly diagnosed breast cancer patient is useful and possible in practice. J Clin Oncol 23(13): 3165-3166.

94. Sand, SR, DeRam, DS, MacDonald, DJ, Blazer, KR, Weitzel, JN. (2005). Linkage of a pedigree drawing program and database to a program for determining BRCA mutation carrier probability. Familial Cancer 4(4): 313-316.

95. Weitzel, J. N., M. Robson, Pasini, B. …Narod, SA. (2005). A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiology, Biomarkers & Prevention 14(6): 1534-8.

96. Weitzel, J. N., V. Lagos, ...Neuhausen, SL. (2005). Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev 14: 1666-1671.

97. Martinez, S. L., J. Herzog, Weitzel, JN. (2004). Loss of five amino acids in BRCA2 is associated with ovarian cancer. J Med Genet 41(2): e18.

98. Loo, J. C., L. Liu, …Weitzel, JN, ...Hogg, D. (2003). Germline splicing mutations of CDKN2A predispose to melanoma. Oncogene 22(41): 6387-6394.

99. Weitzel, J. N., S. M. McCaffrey, …Cullinane, CA. (2003). Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Archives of Surgery 138(12): 1323-8; discussion 1329.

100. Foulkes, W. D., I. Thiffault, ...Weitzel, JN, ...Ellis, NA.. (2002). The Founder Mutation MSH2*1906G-->C Is an Important Cause of Hereditary Nonpolyposis Colorectal Cancer in the Ashkenazi Jewish Population. Am J Hum Genet 71(6): 1395-1412.

101. Herzog, J. S., E. M. Jancis, ...Weitzel, JN. (2002). Restriction endonuclease fingerprinting enhanced conformation sensitive gel electrophoresis (REF-CSGE) in the analysis of BRCA1 exon 11 mutations in a high-risk breast cancer cohort. Human Mutation 19: 656-63.

102. Narod, S. A., M. P. Dube,...Weitzel, JN,... Brunet, JS. (2002). Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 carriers. J Natl Cancer Inst 94(23): 1773-1779.

ABSTRACTS

103. Solomon I, Nehoray N, Niell-Swiller M…Weitzel JN (2015) Best Practices in Genetic Cancer Risk Assessment: Delivery Models and Barriers in Community Settings. American Society of Human Genetics Annual Meeting; 2015 October; Baltimore, MD, USA

104. Slavin TP, Maxwell KN…Weitzel JN. (2015) How big of a role does TP53 play in BRCA1/2 negative familial breast cancer? Data from the SIMPLEXO consortium. Poster # 2588T. American Society of Human Genetics Annual Meeting; 2015 October; Baltimore, MD, USA

105. Solomon I, Sunga A, Yang K, Ryback C, Weitzel JN. (2014) Excess Prevalence of Gastric Cancer Family History Among Hispanic Breast Cancer Patients. Paper presented at: 64th Annual Meeting of the American Society of Human Genetics; October 18-22, 2014; San Diego, CA.

106. Juarez, G., M. Perez, …Weitzel, JN. (2009) Culturally Relevant Cancer Risk Counseling for Underserved Latinas. Paper presented at: International Institute for Qualitative Methodology 15th Annual Qualitative Health Research Conference; October 8-10, 2009; Vancouver, BC Canada

107. Lagos, V. I., K. R. Blazer, ...Weitzel, JN. (2008) Impact of genetic cancer risk assessment on cancer screening and prevention behaviors in an underserved predominantly Latina population. Paper presented at: National Latino Cancer Summit; July 30 - Aug. 1, 2008; San Francisco, CA.

108. MacDonald, D. J., J. Culver, ...Weitzel. (2008). Development Of A Decision Aid For BRCA+ Women With Breast Cancer: An update. Paper presented at: International Society of Nurses in Genetics (ISONG) 21st Annual Educational Conference; November 8-11, 2008; Philadelphia, PA.

109. Szabo, C., K. Kubalanza, …Weitzel, JN, …Couch, F. (2008). Beyond BRCA1 and BRCA2: identification of novel breast cancer susceptibility genes through candidate gene analyses. Paper presented at: AACR 99th Annual Meeting; April 12, 2008; San Diego, CA.

110. Burke H, Hoang A, Metcalfe K, ...Weitzel, JN. (2007) Individualized risk predictions to estimate the clinical benefit of risk reduction mastectomy (RRM) and oophorectomy (RRSO) in BRCA carriers with breast cancer. Poster presented at: American Society of Human Genetics 57th Annual Meeting; October 23-27, 2007; San Diego, CA.

111. Lowstuter K, Lagos VI, Gambol PJ, MacDonald D, Weitzel JN. (2006) Sharing Colorectal Cancer Risk Information with Family Members: Barriers, Facilitators, and Influence of Family Hardiness. Paper presented at: National Society of Genetic Counselors 25th Annual Education Conference; November 10-14, 2006; Nashville, TN.

112. Perez MA, Lagos VI, Weitzel JN. (2006) Social-Cognitive Predictors of Perceived-Access in Underserved Women Undergoing Genetic Counseling. Poster presented at: American Psychological Association 114th Annual Convention; August 10-13, 2006; New Orleans, LA.

113. Weitzel JN, Lagos V, Blazer KR, …Perez, M. (2006) Impact of Genetic Cancer Risk Assessment on Cancer Screening and Prevention Behaviors in an Underserved Predominantly Latina Population. Paper presented at: AACR Frontiers in Cancer Prevention Research; November 2006; Boston, MA.

114. Ricker C, Lagos V, Fuentes S, …Weitzel, JN. Meeting a Need: The Impact of Genetic Cancer Risk Assessment in an Underserved Predominately Latina Population. Poster presented at: ICC 9th Biennial Symposium on Minorities, the Medically Underserved & Cancer: From Awareness to Action, The Unequal Burden of Cancer; March 24-28, 2004; Washington, DC.

115. MacDonald DJ, Sarna L, Uman G, Grant M, Weitzel J. (2004) Characteristics, concerns, and cancer risk reducing practices of women presenting to a comprehensive cancer center for genetic cancer risk assessment. Poster presented at: Oncology Nursing Society 29th Annual Congress; May 11, 2004; Anaheim, CA.

116. Weitzel JN, Lagos VI, Blazer KR, Ricker CN, Saeheng J, MacDonald, DJ. A matter of timing: a prospective study of risk management choices of breast cancer (BC) patients after genetic cancer risk assessment (GCRA). Paper presented at: San Antonio Breast Cancer Symposium--27th Annual Meeting; December 8-11, 2004; San Antonio, TX.

117. Gambol PJ, Cullinane CA, Lagos V, Weitzel JN. Family structure as a predictor of the presence of deleterious BRCA mutations in single case indicators. Paper presented at: American Society of Clinical Oncology--39th Annual Meeting; May 31-June 3, 2003; Chicago, Illinois.

118. Nedelcu R, Buzin CH, Wen CY, Estaki B, Sommer SS, Weitzel J. (2003) MSH6 Mutation Analysis in a Clinical Series of High-Risk Hereditary Colon Cancer Families. Poster presented at: American Association of Cancer Researcher--94th Annual Meeting; July 11-14, 2003; Washington, D.C.

119. Jancis EM, Somlo G, Herzog J, ...Weitzel, JN. (2002) BRCA1 mutational analysis in a cohort of high breast cancer (HRBC) patients treated with high dose chemotherapy (HDCT) and autologous stem cell rescue. Poster presented at: American Society of Clinical Oncology--38th Annual Meeting; May 18-21, 2002; Orlando, Florida.

120. Weitzel JN, Somlo G, Krontiris TG,...MacDonald, DJ. (1998) Family history (FH) in a cohort of high risk breast cancer (HRBC) patients treated with high dose chemotherapy (HDCT) and stem-cell rescue. Poster presented at: American Society of Clinical Oncology--34th Annual Meeting; May 16-19, 1998; Los Angeles, CA.